Summit Therapeutics Inc. (SMMT) Stock Overview
Explore Summit Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Summit Therapeutics Inc. (SMMT)
Key Financials
Key Financials
Market Cap
14.7B
P/E Ratio
-15.72
EPS (TTM)
$-1.12
ROE
-2.04%
SMMT Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Summit Therapeutics Inc. (NASDAQ: SMMT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Summit Therapeutics Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of SMMT on the NASDAQ shows an RSI of 70.84, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $13.25 for the NASDAQ listing.
Key metrics behind Summit Therapeutics Inc.'s NASDAQ-traded stock include a P/E ratio of -15.72 and a market capitalization of 14.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of SMMT on the NASDAQ.